Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity.

Tamoxifen is administered for estrogen receptor positive (ER+) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER+ breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration. In this study, we found that anordrin, marketed as an antifertility medicine in China, inhibited tamoxifen-induced endometrial epithelial cell mitosis and NAFLD in mouse uterus and liver as an anti-estrogenic and estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, the active metabolite of anordrin, weakly bound to the ligand binding domain of ER-α. Anordrin did not regulate the classic estrogen nuclear pathway; thus, it did not affect the anti-tumor activity of tamoxifen in nude mice. Taken together, these data suggested that anordrin could eliminate the side effects of tamoxifen without affecting its anti-tumor activity.

Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.

The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated. ORG 31806 at a dose of 2 mg/kg/day, mifepristone at 4 mg/kg/day, and onapristone at 8 mg/kg/day, terminated pregnancy in all treated animals. Anordiol, an antiestrogen, at a dose of 5 mg/kg/day, terminated pregnancy in all treated animals. Anordiol acted synergistically with all three antiprogestins terminating pregnancy in the rat. The antiprogestins at doses that were either partially effective or non-effective became 100% effective when administered with a non-effective dose of anordiol. Thus, combination of ORG 31806 (1 mg/kg/day) plus anordiol (0.31 mg/kg/ day), mifepristone (1 mg/kg/day) plus anordiol (0.62 mg/ kg/day), and onapristone (2 mg/kg/day) plus anordiol (2.5 mg/kg/day) terminated pregnancy in all treated animals. These combinations of the antiprogestins and anordiol decreased significantly the serum progesterone levels but not serum 17 beta-estradiol levels. The present results indicate that the most potent combination was ORG 31806 plus anordiol.

PIP: The pregnancy termination potency of varying doses of mifepristone, onapristone, and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated in adult rats. The antiprogestins and anordiol alone were administered to pregnant female rats on days 7, 8, and 9 of pregnancy and the presence or absence of embryos in utero was determined on day 16. ORG 31806 at a dose of 2 mg/kg/day, mifepristone at 4 mg/kg/day, and onapristone at 8 mg/kg/day terminated pregnancy in 100% of animals; 5 mg/kg/day of anordiol was required. Anordiol acted synergistically with all three antiprogestins. Antiprogestin doses that were either partially effective or ineffective became 100% effective when administered with a noneffective dose of anordiol. The combination of ORG 31806 (1 mg/kg/day) and anordiol (0.31 mg/kg/day) had the most potent pregnancy termination activity. The administration of antiprogestins in combination with anordiol at doses that effectively terminate pregnancy was associated with a significant, persistent reduction in serum progesterone, but no change in serum estradiol levels. The effectiveness of ORG 31806 and anordiol in terminating pregnancy should be evaluated in a non-human primate model to determine its potential clinical use.

Anti-implantation activity of antiestrogens and mifepristone.

To develop a better postcoital contraceptive, the following antiestrogens were tested for their anti-implantation activity in the rat: anordrin, anordiol, tamoxifen, ICI 182,780, and RU 39411. The compounds were administered orally or subcutaneously (s.c.) to female rats on days 1, 2, and 3 of pregnancy. All the antiestrogens tested were 100% effective in preventing blastocyst implantation. The lowest effective doses when administered orally were 10, 1.25, 0.062, 6.0 (partially effective), and 0.01 mg/kg/day, respectively. The estimated median effective doses (ED50) were 5.60, 0.40, 0.035, 5.40, and 0.0074 mg/kg/day, respectively. When administered s.c., the minimum effective doses in preventing blastocyst implantation in all animals were 2.0, 0.1, 0.1, 0.1, and 0.01 mg/kg/day, respectively. Anordrin, anordiol, and ICI 182,780 were more potent when administered s.c.; whereas tamoxifen and RU 39411 were effective at similar doses when administered parenterally or orally. RU 39411 was the most potent among the antiestrogens tested and should be evaluated as a potential postcoital contraceptive. The administration of mifepristone, an antiprogestin, at a dose of 8 mg/kg/day blocked blastocyst implantation in all treated animals; whereas at a dose of 4 mg/kg/day or lower, the drug was ineffective. These findings confirm that estradiol and progesterone are essential for blastocyst implantation in the rat. The capacity of mifepristone to potentiate the anti-implantation activity of the antiestrogens was also determined. The combination of a non-effective dose of each of the antiestrogens (anordrin, anordiol, and tamoxifen), and RU 39411, with mifepristone at a non-effective dose, prevented pregnancy, demonstration that an antiprogestin and antiestrogen act synergistically in blocking blastocyst implantation in the rat. The antiestrogen compounds whose anti-implantation activities were potentiated by mifepristone were found to possess significant estrogenic activity, when assayed by measuring the increase in the uterine weights of ovariectomized rats. The only exception was ICI 182,780, which showed no estrogenic activity in the uterine weight bioassay and did not act synergistically with mifepristone in blocking blastocyst implantation. Estradiol was effective in preventing pregnancy at a dose of 1 microgram/kg/day. The combination of non-effective doses of estradiol and mifepristone did not prevent pregnancy. The findings that mifepristone potentiates the anti-implantation activity suggests that the synergistic effect may be a unique property of this class of antiestrogens.

PIP: In New York, female and male rats copulated on the afternoon of proestrus as part of a study aiming to determine whether antiestrogens alone or in combination with mifepristone (RU-486) will block blastocyst implantation in the rat. This study is part of research efforts to develop a better postcoital contraceptive. The antiestrogens included RU39411; ICI 182,780; anordrin; anordiol; tamoxifen; and estradiol. The laboratory researchers treated the rats orally or subcutaneously on days 1, 2, and 3 of pregnancy. They killed them on day 8-9 to examine the uteri for the presence or absence of implanted embryos. All the antiestrogens effectively prevented blastocyte implantation. Using the measurement mg/kg/day, the lowest effective oral dose was 10 for anordrin; 1.25 for anordiol; 0.062 for tamoxifen; 6 (80% effective) for ICI 182,780; and 0.01 for RU 39411. These antiestrogens' estimated median effective doses were 5.6, 0.4, 0.035, 5.4, and 0.0074 mg/kg/day, respectively. In all animals, the minimum effective doses administered subcutaneously were 2, 0.1, 0.1, 0.1, and 0.01 mg/kg/day, respectively. Anordrin, anordiol, and ICI 182,780 were more effective during subcutaneous administration while tamoxifen and RU 39411 were as effective at similar doses during parenteral or oral administration. The most potent antiestrogen was RU 39411. This antiestrogen should be evaluated as a potential postcoital contraceptive. An 8 mg/kg/day dose of RU-486 blocked blastocyst implantation in all rats. The 4 mg/kg/day dose was completely ineffective. RU-486 augmented the activity of anordrin, anordiol, tamoxifen, and RU39411 synergistically, resulting in prevention of pregnancy at non-effective doses of RU-486 and the antiestrogens. These same antiestrogens also exhibited significant estrogenic activity as determined by an increase in uterine weights of ovariectomized rats. Estradiol prevented pregnancy at a dose of 1 mcg/kg/day. RU-486 did not potentiate estradiol. These findings suggest that the synergistic effect of anordrin, anordiol, tamoxifen, and RU39411 may be unique to these antiestrogens.

Anordiol and RU486 synergize to produce preimplantation pregnancy loss by increasing embryo transport (rat).

RU486, an antiprogestational agent, and anordiol (dihydroxylated metabolite of anordrin) which has an estrogenic and antiestrogenic activity, are known to inhibit fertility. These agents were administered orally, alone or together, to rats prior to implantation, on Day 2 of pregnancy. Control animals were fed with the vehicle only. The effectiveness of the agents in terminating pregnancy in female rats was determined on Day 14 of pregnancy. Anordiol presented a dose-dependent effect on abolishing pregnancy, being 100% effective at 2.5 mg/Kg and non-effective at 0.6 mg/Kg. RU486 did not prevent pregnancy even at a dose of 4 mg/Kg. Doses of RU486 and anordiol that were ineffective when administered alone, prevented pregnancy in 70% of the rats when these agents were given together. To determine the mechanism by which these drugs prevent pregnancy, oviducts and uteri of rats were examined for presence of embryos on Day 3 of pregnancy. Only 29% of embryos were recovered from the oviducts of rats treated with 2.5 mg/Kg anordiol (compared to 89% in control group) plus an additional 9% from the uteri. In combination, anordiol and RU486 had a synergistic effect on embryo transport in the rats' reproductive tract, without any apparent accumulation in the uterus. These results led us to conclude that the pregnancy preventing action of anordiol plus RU486 is mostly due to accelerated transport of the embryos in the reproductive tract prior to implantation.

Termination of early pregnancy in the rat, rabbit, and hamster with RU 486 and anordrin.

The effectiveness of oral RU 486 and anordrin given alone and in combination for terminating early pregnancy was tested in the rat, rabbit, and hamster. In the rat and rabbit, the combination of RU 486 and anordrin is more effective in terminating pregnancy than either of the two compounds used alone. A non-effective dose of RU 486 combined with a non-effective or a sub-effective dose of anordrin, or a low effective dose of RU 486 in combination with a non-effective dose of anordrin, exerted additive or synergistic effects resulting in resorption of embryos and termination of pregnancy in rats and rabbits. The serum progesterone as well as estradiol concentrations were significantly suppressed by these combinations when pregnancy was terminated. In the hamster, however, RU 486 was not effective in interrupting early pregnancy, even at a 4-fold higher dose than was effective in the rat, due to the fact that RU 486 does not bind to the progestin receptor in this species. Unexpectedly, there were also no effects of anordrin on pregnancy termination in the hamster even at high doses. It is concluded that in rat and rabbit, the synergistic action between RU 486 and anordrin not only greatly enhances efficacy in terminating pregnancy but also reduces substantially the doses required to produce this effect.

Anordiol is more potent than anordrin for terminating pregnancy when administered with RU 486.

In view of the unexpected ability of anordrin to synergize with RU 486 in terminating pregnancy, it was pertinent to examine the actions of the dihydroxylated metabolite of anordrin, anordiol, alone and in combination with RU 486. Does of RU 486 (1 mg/kg/day) and anordiol (0.6 mg/kg/day) that were ineffective when given alone terminated pregnancy with complete resorption of embryos when administered together. A smaller dose of anordiol than anordrin is required to achieve this synergistic effect with RU 486. This anordrin metabolite increased uterine weight in the ovariectomized rat similar to estradiol. The estrogenicity of anordiol in the uterine weight assay was about 1/120 of that of estradiol. Anordiol does not exert antiestrogenic activity in the uterine weight assay when administered at doses that terminate pregnancy. Administration of anordiol at doses that do not terminate pregnancy resulted in a significant suppression of serum progesterone concentrations during the period of medication; these observations suggest that anordiol has an inhibitory effect on progesterone biosynthesis. When the same dose of anordiol was given concomitantly with sufficient RU 486 (e.g., 1 mg/kg/day) to terminate pregnancy, the progesterone levels were reduced to low levels throughout the experiment. These observations support the postulate that the actions of anordrin are mediated by its metabolite, anordiol. The administration of anordiol plus RU 486 results in a more dramatic change in the functional progesterone:estradiol ratio than when either agent is administered alone.

Additive effect of RU 486 and anordrin on pregnancy interruption in the mouse.

The effect of various doses of anordrin and RU 486, alone or combined, on serum progesterone (P) levels, fetal resorption, and recovery of ovulation was studied in mice. Each drug was given as a single sc injection on day 7 of pregnancy and autopsy was performed on days 8, 9, or 11. Serum P was normal at 24 h but fell significantly 48 h after treatment with anordrin (0.05 mg). Doses of 0.05 or 0.2 mg anordrin were effective in interrupting pregnancy in 30% and 70% of pregnant mice, respectively. RU 486, 0.01 mg per mouse, induced a pronounced decrease of P levels 24 h after treatment and interrupted pregnancy in 50% of pregnant mice. The combined treatment with submaximal doses of anordrin plus RU 486 did not further decrease P levels, but increased the proportion of mice with fetal resorptions to 90%. The combination of small doses of anordrin with RU 486 had an additive effect on pregnancy termination. The additive effect required a dose of RU 486 above the threshold level. Direct observation of aborted fetuses indicated that the resorptive process occurred earlier with RU 486 than with anordrin. Recovery of ovulation was associated with pregnancy termination in a high proportion of mice treated with either drug or their combination.

[Studies on anordrin injection for termination of early pregnancy in mice].

In order to increase the effectiveness on the termination of early pregnancy, anordrin injection was prepared. A nonaqueous solvent was selected as the parenteral solvent which was not irritating and toxic. The security test showed the injection was also not irritating and toxic. After the injection was heated for 76 h in 95 +/- 2 degrees C water or stored for 3 mon at 37 degrees C, the content of anordrin showed no change. The activation energy of the injection was 68.1 kJ/mol determined by thermogravimeter analysis. This also showed that the injection was steady. Results of termination of early pregnancy in mice showed that a single dose of anordrin injection (3 mg/kg) intraperitoneally was more effective than a single dose of anordrin tablet (3 mg/kg) orally (P less than 0.01). Histological studies showed that embryo, decidual cells and nutrient cells were markedly degenerated or dead when treated with the injection (3 mg/kg) intraperitoneally.

[Studies on coprecipitate of anordrin-PVP].

The coprecipitate of anordrin (AD)-PVP was prepared by solvent method. The DSC (differential scanning calorimetry) revealed that AD did not have crystalline structure in coprecipitates of 1:7-1:9. X-ray diffraction spectrum of 1:8 coprecipitate (COPPT) showed no crystalline structure of AD. The dissolution rate of AD was about 38 times higher for 1:8 COPPT than pure AD. Activation energies determined by DTG (derivative thermogravimetry) were 182.8 and 133.4 kJ/mol, respectively, showing that the 1:8 COPPT is much more stable than pure AD in thermal degradation. The experimental results showed that anti-implantation effect of the 1:8 COPPT was much better than that of AD tablets: the number of implantation sites of mice administrated 1:8 COPPT (5 mg/kg) was 0.2 (P less than 0.01) and that of mice administrated AD tablets (10.6 mg/kg) was 0.9 (P less than 0.05); effective dose of 1:8 COPPT was less than half of that of AD tablets.

Effects of anordrin and its analogue on antifertility.

Anordrin has been used as an effective postcoital contraceptive in China. The mechanism of anordrin and its analogue SIPPR-113 on antifertility has been studied. Anordrin and SIPPR-113 possessed estrogenicities and induced decrease in serum progesterone levels in rats. Their antiprogesterone activities might be mainly caused by their estrogenicities, which were the main but not the only contributors for the antifertility. The direct effects of anordrin and SIPPR-113 on human trophoblast cells were studied. A concentration of 50 micrograms/ml or 100 micrograms/ml of anordrin or SIPPR-113 could injure the human trophoblast cells in vitro. The uterine Pontamine blue reaction of mated rats was inhibited in those treated with anordrin or SIPPR-113 at the dose of 4 mg/kg. Anordrin, SIPPR-113 or AF-45 was given orally, intramuscularly and intravenously. The effects of drugs administered via the three routes were nearly the same. This study further demonstrated that anordrin was hydrolyzed to break its bond of dipropionate and was transformed into its parent steroid AF-45 to exert its antifertility effects in vivo. This study warrants that anordrin should been evaluated further.

[Effect of steroids with anti-androgenic properties on the androgenic and myotrophic activity of testosterone and its various derivatives]. / Vliianie steroidov s antiandrogennymi svoistvami na androgennuiu i miotroficheskuiu aktivnost' testosterona i nekotorykh ego proizvodnykh.

Experiments were conducted on castrated male rats. The effect of antiandrogen 17,17-dimethyl-18-norandrostadien-4,13-one-3 on the androgenic and myotrophic activity of testosterone and of some of its modified analogues, preparations with anabolic action, was studied. The intensity of the antihormonal effects depended not only on the antiandrogen dose used, but also on the dose of the agonist preparation. The author suggests a modification of the method used to assess the biological action of antiandrogens, consisting in a single administration of the "anabolic" preparation with a prolonged action and a 7-day administration of antiandrogen to castrated animals.